Clinical Trial Update: Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of azacitidine combined with pembrolizumab and epacadostat in advanced solid tumors was terminated. Results were posted in March 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Epacadostat (epacadostat)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Incyte Corporation | Conditions: Solid Tumors, Advanced Malignancies | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-03-05